Life-science investment platform · sponsored by Agile Dynamics
Fund life science from a treasury built to last
AgileBio Tech pairs a regulated Bitcoin treasury, structured in Hong Kong, with hands-on venture building. Science is funded through milestone-gated tranches, never through a fixed dividend.
Ways to invest
Choose how you take part
Four routes into the platform, from the treasury fund to co-investing in single assets. Pick one to filter the marketplace.
Marketplace
Investment opportunities
Download each opportunity sheet as a PDF from its card. Sample companies are illustrative archetypes from our strategy, not live deals.
Tickets, timelines and returns marked as placeholders or illustrative are examples, not forecasts. Photos are illustrative.
Operating model
How money moves from treasury to science
One vehicle, two pools with different jobs, and a venture builder that does the hands-on work.
Capital in
Qualified investors commit once to a regulated Hong Kong fund vehicle.
Treasury engine
Bitcoin plus a T-bill reserve of 42.9% at launch, with no Bitcoin sold in a down quarter.
Spending rule
The science budget follows smoothed treasury value, starting near US$1.5M a year at the 3% floor.
Milestone gate
An independent scientific board verifies each milestone before the next tranche is released.
Licence upfronts, milestone income and capped revenue shares from companies that already sell.
A managed distribution moves with the treasury, so losses are not passed to the science.
Agile Dynamics runs regulatory, business development, launch and finance services for every portfolio company.
Jurisdiction · Hong Kong
Why we are building in Hong Kong
Hong Kong combines a simple tax system, ready-made fund structures, a licensed regime for digital assets and Asia’s deepest market for biotech listings.
Summary only; the final structure is subject to Hong Kong tax and legal advice.
Profits tax of 8.25% on the first HK$2 million and 16.5% above it. No capital gains tax and no withholding tax on dividends.
Open-ended fund companies and limited partnership funds, with a unified fund tax exemption. A 2026 bill would add digital assets; it is not yet law.
The Securities and Futures Commission licenses managers and platforms, a regulated route to Bitcoin exposure.
84 biotech companies listed under HKEX Chapter 18A by January 2026, raising more than US$17.5 billion since 2018.
Close to Mainland China and Asian licensees, and home of the AXION Technology Foundation, co-founded by Agile Dynamics.
Governance
The people who pick deals do not hold or value the money
A board with an independent majority, three committees and independent providers keep governance, investment and operations apart.
Independent majority; owns strategy and risk.
Approves every tranche. The sponsor cannot approve its own deals.
Verifies each milestone and has no vote on capital.
An independent custodian holds the assets; an SFC-licensed manager runs the mandate.
Roadmap
Four phases from formation to first deals
Nothing is invested in science before the treasury closes at US$50M or more.
Legal setup
Tax and regulatory opinions obtained; Hong Kong fund vehicle and venture builder formed; board and committees in place.
Capitalization
Costs capped at US$0.50M a year; custodian and manager signed; binding commitments of US$50M or more.
Sourcing and diligence
30–50 co-investors, three lead investors, university frameworks and a biotech vehicle of US$4M or more.
Launch and run
First go-to-market deals and R&D tranches, quarterly reports and the first verified milestone.
Get in touch
Start a conversation
Tell us whether you are an investor, a scientific partner or a growth company. We offer a 90-minute working session on structure, governance and the first deals.
